Kezar Life Sciences (KZR) to Release Quarterly Earnings on Tuesday

Kezar Life Sciences (NASDAQ:KZR) is projected to post its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Kezar Life Sciences to post earnings of ($1.81) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 4:00 PM ET.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($1.87) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $0.28. On average, analysts expect Kezar Life Sciences to post $-4 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Kezar Life Sciences Price Performance

KZR traded down $0.04 on Tuesday, hitting $6.09. 12,424 shares of the stock were exchanged, compared to its average volume of 79,582. Kezar Life Sciences has a 12 month low of $3.53 and a 12 month high of $7.65. The business has a 50-day moving average of $4.49 and a two-hundred day moving average of $4.36. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.29 and a quick ratio of 7.29. The firm has a market capitalization of $44.58 million, a price-to-earnings ratio of -0.63 and a beta of 0.70.

Analyst Ratings Changes

Several research analysts have commented on KZR shares. Jefferies Financial Group downgraded Kezar Life Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $18.00 to $7.00 in a research note on Friday, October 17th. Wall Street Zen raised shares of Kezar Life Sciences to a “sell” rating in a research report on Saturday, September 13th. William Blair restated a “market perform” rating on shares of Kezar Life Sciences in a report on Friday, October 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kezar Life Sciences in a report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a report on Wednesday, July 16th. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $6.00.

Institutional Investors Weigh In On Kezar Life Sciences

An institutional investor recently bought a new position in Kezar Life Sciences stock. Woodline Partners LP purchased a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,555 shares of the company’s stock, valued at approximately $125,000. Woodline Partners LP owned about 0.35% of Kezar Life Sciences at the end of the most recent quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.